Hospital

By aligning the pharmacy revenue cycle with the 340B Drug Pricing Program, organizations can maximize revenue capture from medications while ensuring compliance with 340B requirements, leading to enhanced financial performance and improved care for underserved populations.

Pharmacists are essential in preventing the significant health and economic burden of respiratory syncytial virus (RSV) infections in older adults through vaccination.

A study in Lancet Haematology revealed that minority ethnic patients face significantly poorer outcomes after hematopoietic cell transplantation compared to White patients.

VGT-1849A could reduce JAK2 activity, lessening the disease burden faced by individuals with PV while providing a favorable safety profile.

Clinical trials will seek to evaluate the immunogenicity and safety of the LBT-SA7 vaccine.

Rates of GBS were similar between Arexvy and Abrysvo, at 0.12% and 0.11% of total reported events, respectively.

Varicella-zoster vaccination could prevent fatal outcome among individuals with disseminated herpes zoster.

The decision is based off favorable results from the BREAKWATER trial.

Pharmacists identify appropriate patients for new oral and antibody drug conjugate treatments and provide counseling to help patients navigate the evolving treatment landscape.

Compounding pharmacies play a vital role in meeting the unique needs of patients, but pharmacists must adhere to strict safety standards and regulations.

The approval follows positive results from the V005 (NCT03005418) clinical trial.

This case highlights the importance of recognizing ICPI-AKI, implementing effective therapeutic interventions, and understanding the clinical context to prevent irreversible renal damage.

The findings show a need for researchers and health care professionals to consider model designs to minimize disparities when diagnosing perinatal mood and anxiety disorders (PMADs).

The rare genetic disease is a severe hypertriglyceridemia that can lead to potentially life-threatening acute pancreatitis.

The evolving regulatory policies around biosimilar interchangeability is crucial for driving successful biosimilar adoption in the marketplace.

Phage therapy, which uses lytic bacteriophages to target antibiotic-resistant bacteria, has resurfaced as a promising treatment for multidrug-resistant infections, but faces challenges in regulation, production, and clinical implementation despite its growing evidence of efficacy.

Previously, the evidence to support the prediction with lactate-to-albumin ratio has been unclear.

The approval makes remestemcel-L-rknd the first approved mesenchymal stromal cell in the United States.

Pharmacy professionals deserve the right to pursue mental health care without fear of losing their jobs. The Wellbeing First Champion Challenge is helping change this.

Pharmacy errors can happen due to manual processes, but they can be mitigated through adoption of automated IV workflow technology and comprehensive compounding records.

Clesrovimab would be the first and only single dose immunization indicated for infants regardless of weight, aimed to protect against their first RSV season.

The findings suggest that VZV is a common cause of CNS infections, even when there is no visible rash.

Standardizing observational competencies and utilizing technology to improve compounding accuracy can ensure safety and quality of compounded medications.

Ustekinumab-stba (Steqeyma; Celltrion) is a subcutaneous treatment for adult and pediatric patients with plaque psoriasis arthritis, psoriatic arthritis, Crohn disease, and ulcerative colitis.

Higher costs of efgartigimod alfa are primarily driven by its status as a newly approved, brand-name therapy without a generic alternative.

Food insecurity in rural communities can affect hypertension, but pharmacists can mitigate the impact by educating themselves on nutrition options for low-income individuals.

The decision is based on positive results from the CAHtalyst trials, which both met their primary and secondary end points.

The conversation of VLR has sparked a discussion as to whether or not other COVID-19 treatment agents are associated with a surge in symptoms and if so, how those agents compare with the rebound effect of nirmatrelvir/ritonavir.

Snehal Bhatt discusess the need to individualize antiplatelet therapy decisions based on a comprehensive assessment of each patient's unique risk factors for thrombosis and bleeding.

Measuring end points such as molecular response, cytokines, and histomorphometry may show a greater range of benefits.